Manufacturer : Novo Nordisk

Basic substance : Somatropin 

package : 1 x 30mg/3ml*pen

Category :HGH 


NORDITROPIN is a polypeptide hormone of recombinant DNA.





Norditropin Nordilet Pen 30MG/ a disposable, premixed, prefilled pen that makes taking growth hormone simple. Norditropin Nordilet Pen and 5 mg delivery pens are the only prefilled, multi-dose, disposable growth hormone pens that, after initial use, can be stored at up to 77°F for use within 3 weeks Unlike other growth hormone delivery pens.

The hormone( DNA). is synthesized by a special strain of E. coli bacteria that has been modified by the addition of a plasmid which carries the gene for human growth hormone. Norditropin contains the identical sequence of 191 amino acids constituting the naturally occurring pituitary human growth hormone with a molecular weight of about 22,000 Daltons.

Norditropin Nordilet Pen is pefilled and premixed. This means you don’t have to load the growth hormone with cartridges Users of Norditropin Nordilet Pen  have access to NordiCare patient support, which can help you with Norditropin Nordilet Pen  insurance issues you may have Norditropin Nordilet Pen offers multiple doses which means most patients can use the pen several times before the medicine runs out.

In people with growth hormone deficiency, Norditropin Nordilet Pen  (somatropin [rDNA origin] injection) replenishes the growth hormone that the body isn’t making.

HGH is made in the pituitary gland that is located at the base of your brain. This hormone is responsible for all the growth of the body, this includes bones and organs, and it helps a lot in the body´s metabolic process. After the growth hormone is released from your pituitary gland, then the hormone tells to your liver to release a second hormone which is called IGF-1. Then together, these hormones tell your organism to grow by adding more cells to the bones and tissues. Norditropin pens are one of our best sellers and are available for Northamerican customers only.


Uses and dosage :

For subcutaneous injection. Therapy with Norditropin should be supervised by a physician who is experienced in the diagnosis and management of pediatric patients with short stature associated with GHD, Noonan syndrome, Turner syndrome or SGA, and adult patients with either childhood onset or adult onset GHD.

Dosing of Pediatric Patients
General Pediatric Dosing Information
The Norditropin dosage and administration schedule should be individualized based on the growth response of each patient. Serum insulin-like growth factor I (IGF-I) levels may be useful during dose titration.

Response to somatropin therapy in pediatric patients tends to decrease with time. However, in pediatric patients, the failure to increase growth rate, particularly during the first year of therapy, indicates the need for close assessment of compliance and evaluation for other causes of growth failure, such as hypothyroidism, undernutrition, advanced bone age and antibodies to recombinant human GH (rhGH).

Treatment with Norditropin for short stature should be discontinued when the epiphyses are fused.

Pediatric Growth Hormone Deficiency (GHD)
A dosage of 0.024 to 0.034 mg/kg/day, 6 – 7 times a week, is recommended.

Pediatric Patients with Short Stature Associated with Noonan Syndrome
Not all patients with Noonan syndrome have short stature; some will achieve a normal adult height without treatment. Therefore, prior to initiating Norditropin for a patient with Noonan syndrome, establish that the patient does have short stature. A dosage of up to 0.066 mg/kg/day is recommended.

Pediatric Patients with Short Stature Associated with Turner Syndrome
A dosage of up to 0.067 mg/kg/day is recommended.

Pediatric Patients with Short Stature Born Small for Gestational Age (SGA) with No Catch-up Growth by Age 2 to 4 Years
A dosage of up to 0.067 mg/kg/day is recommended.

Recent literature has recommended initial treatment with larger doses of somatropin (e.g., 0.067 mg/kg/day), especially in very short children (i.e., HSDS < -3), and/or older/pubertal children, and that a reduction in dosage (e.g., gradually towards 0.033 mg/kg/day) should be considered if substantial catch-up growth is observed during the first few years of therapy. On the other hand, in younger SGA children (e.g., approximately < 4 years) (who respond the best in general) with less severe short stature (i.e., baseline HSDS values between -2 and -3), consideration should be given to initiating treatment at a lower dose (e.g., 0.033 mg/kg per day), and titrating the dose as needed over time. In all children, clinicians should carefully monitor the growth response, and adjust the rhGH dose as necessary.


Side effects:

common side effects :

Body aches or pain
breast pain
change in the color, amount, or odor of vaginal discharge
discoloration of the fingernails or toenails
dryness or soreness of the throat
excess air or gas in the stomach or intestines
frequent urge to defecate
increased sweating
passing gas
straining while passing stool
stuffy nose
tender, swollen glands in neck
trouble with swallowing
voice changes




There are no reviews yet.

Be the first to review “NORDITROPIN NORDIFLEX PEN 30MG/3ML”

Select your currency
USD United States (US) dollar
EUR Euro